Mycoplasma pneumonia
Conditions
Interventions
Experimental group:Basic treatment+Lianhua Qingke tablets
Dosage: Children under 7 years old: 2 tablets/time, 3 times/day
= 7-year-old children: 4 tablets/time, 3 times/day
Control group:Basic treatment+Lianhua Qingke tablets placebo
Sponsors
Hebei Yiling Hospital
Eligibility
Sex/Gender
All
Age
4 Years to 14 Years
Inclusion criteria
Inclusion criteria: 1. Age between 4 and 14 years old (including both ends); 2. Mild patients who meet the diagnostic criteria for Mycoplasma pneumonia in children; 3. Nasopharyngeal swab sampling, rapid detection of Mycoplasma pneumoniae antigen positive (colloidal gold method), or detection of Mycoplasma pneumoniae IgM antibody positive in fingertip blood. Any positive result from both can be selected. 4. The course of the disease is = 24 hours and = 5 days, and the body temperature has reached 37.3 ? or above (under the armpit); 5. Those who meet the differentiation criteria for wind heat invading the lungs in traditional Chinese medicine; 6. The legal guardian of the child or/and themselves voluntarily participate in the study, and the legal guardian agrees and signs an informed consent form (while children aged = 8 need to voluntarily sign an informed consent form).
Exclusion criteria
Exclusion criteria: 1. Meets the diagnostic criteria for refractory or severe Mycoplasma pneumoniae pneumonia; 2. Chest X-ray or CT shows obvious lung tumors or tuberculosis; 3. Patients with acute infectious diseases such as measles and pertussis; 4. Other respiratory diseases such as acute upper respiratory tract infections, bronchial asthma, and bronchial foreign bodies; 5. Children with severe malnutrition and immunodeficiency; 6. Concomitant severe primary diseases such as heart, liver, kidney, digestive and hematopoietic systems; 7. Patients who have participated or are currently participating in clinical trials of other drugs within the past three months; 8. Allergic constitution (individuals who are allergic to Class 2 or more components of the investigational drug); 9. Researchers believe that individuals should not be included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The relief rate of main symptoms (fever, cough, sputum, headache, pharyngeal redness, swelling and pain, each symptom decreases by one level to be relieved, and maintained for more than 24 hours); | — |
Secondary
| Measure | Time frame |
|---|---|
| The effectiveness rate of traditional Chinese medicine syndrome scoring (a 50% decrease in total score is considered effective);The relief rate and duration of major single symptoms (fever, cough, sputum, headache, pharyngeal redness, swelling and pain);The proportion of severe or critical cases of Mycoplasma pneumonia;CRP change value;Changes in immunoglobulins, lymphocyte subpopulations, interleukins, etc;Changes in fecal microbiota; | — |
Countries
China
Contacts
Public ContactCao Ran
Hebei Yiling Hospital
Outcome results
None listed